. 2022 Mar 14;23:212. doi: 10.1186/s13063-022-06028-y

Table 5.

Safety and other outcomes

	Opioid (n = xxx)	Placebo (n = xxx)	Fisher exact p value
Safety
Serious adverse events (SAEs)	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Related SAEs	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Adverse events (AEs)	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Healthcare utilisation
Physiotherapy	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Imaging	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
General practitioner	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Specialist doctor	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
ED/hospitalisation	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Others	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Use of concomitant medications
Simple analgesia	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
NSAID	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Combination opioid	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Strong opioid	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Others	n^EVT n^PAT (%)	n^EVT n^PAT (%)	0.xxx
Use of health services and concomitant medicines in patients reporting ongoing pain
Week 26	n/N (%)	n/N (%)	0.xxx
Week 52	n/N (%)	n/N (%)	0.xxx
At risk of misuse (scoring ≥9 on COMM)
Week 12	n/N (%)	n/N (%)	0.xxx
Week 26	n/N (%)	n/N (%)	0.xxx
Week 52	n/N (%)	n/N (%)	0.xxx

COMM Current Opioid Misuse Measure